国邦医药: 国邦医药关于调整2024年度利润分配方案每股分配金额的公告

Core Viewpoint - The company has adjusted its profit distribution plan for the year 2024, increasing the cash dividend per share from 0.60000 yuan (including tax) to 0.60583 yuan (including tax) due to changes in the total share capital resulting from share buybacks [1][3]. Summary by Sections Adjusted Profit Distribution Plan - The cash dividend per share has been revised to 0.60583 yuan (including tax) from the previously announced 0.60000 yuan (including tax) [1][3]. - The adjustment is a result of the company's share buyback activities, which altered the total number of shares eligible for profit distribution while keeping the total distribution amount unchanged [1][3]. Previous Profit Distribution Plan - The initial profit distribution plan was approved on March 27, 2025, and April 25, 2025, with a total cash dividend of 335,019,120 yuan (including tax) based on a total share capital of 558,823,500 shares, excluding 458,300 shares held in the buyback account [1][2]. - The plan was based on the total share capital minus the shares in the buyback account, resulting in a base of 558,365,200 shares for the distribution [1][2]. Calculation of Adjusted Dividend - The actual number of shares eligible for distribution is calculated as 558,823,500 shares minus 5,833,574 shares in the buyback account, resulting in 552,989,926 shares [3]. - The adjusted cash dividend per share is calculated by dividing the total cash dividend amount (335,019,120 yuan) by the number of shares eligible for distribution (552,989,926), yielding approximately 0.60583 yuan per share [3]. - The total profit distribution amount remains approximately 335,017,886.87 yuan (including tax) after rounding [3]. Assurance of Distribution Implementation - The company will not engage in any actions that could alter the total share capital or the number of shares in the buyback account from the date of submitting the special application for differentiated rights distribution until the completion of the profit distribution [4].